UTSA Stem Cell Core
The Stem Cell Core provides access to a streamlined, IRB-approved consenting process for acquisition of patient samples and generation of pluripotent stem cells and stem cell-derivatives for basic and preclinical research.
The University of Texas at San Antonio
One UTSA Circle
Science Research Laboratories
San Antonio, TX 78249
Hours of Operation
Monday to Friday, 9:00 a.m. – 5:00 p.m.
For more information about stem cell biology, please visit StemBook, an open access collection of content covering a wide range of topics, for both stem cell and non-stem cell researchers:
About Dr. Navara and the Stem Cell Core
Dr. Christopher Navara has 15 years of experience in pluripotent stem cell research including both humans and non-human primates. To date he has derived or isolated over 50 cell lines from rhesus monkeys, baboons and humans including from patients with Alzheimer's disease Parkinson’s disease and epilepsy. Before coming to UTSA in 2008 Dr. Navara was the director of the Stem Cell core at the Pittsburgh Development Center of Magee Womens Research Institute at the University of Pittsburgh Medical School. Dr. Navara received his bachelor’s degree in molecular biology and a Ph.D. in cellular and molecular biology from the University of Wisconsin-Madison.
Dr. Navara’s research focuses on the cellular biology of pluripotent stem cells. The repeated clinical failures of therapies for Alzheimer’s and Parkinson’s disease indicate the need for additional preclinical models of these complex conditions. Parkinson’s disease is a progressive degenerative disease resulting in the loss of nerve cells in the brain. Samples from human patients are difficult to obtain and animal models may not faithfully mimic the disease. Using human pluripotent stem cells, Dr. Navara’s research group makes human nerve cells from Parkinson’s patients, test their biology to better understand the disease, and test new potential therapies that may slow or stop its progression.
Pluripotent stem cells also hold great promise for the treatment of diseases ranging from diabetes to Parkinson’s disease. Dr. Navara’s group is using non-human primates as preclinical models for the safe testing and optimization of these therapies prior to use in the clinic. Recently, he differentiated these iPSC lines into fully functional dopaminergic neurons (Grow et al., 2016 Stem Cells – Translation Medicine) and demonstrated these cells express the neuronal genes TUBB3, MAP2, TH, and KCNJ6. They also have spontaneous and induced action potentials and they release catecholamines upon stimulation as assessed by cyclic voltammetry. Currently, he is transplanting these cells back into the animals from which they are derived.